Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
BB Biotech AG: A reportable insider transaction was published on 6th March 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 6th March 2025,
The Insider Transaction was made by von Planta, Dr. Thomas 
. The transaction toke place on 5th March 2025. The order was executed at the trading place SIX Swiss Exchange,. . The aggregated volume was 40.893,80 CHF, based on an average price of 36,77 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 18th September 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 18th September 2024,
The Insider Transaction was made by von Planta, Dr. Thomas . The transaction toke place on 16th September 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 47.103,20 CHF, based on an average price of 37,86 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 31st July 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 31st July 2024,
The Insider Transaction was made by von Planta, Dr. Thomas . The transaction toke place on 29th July 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 54.913,50 CHF, based on an average price of 44,14 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 2nd May 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 2nd May 2024,
The Insider Transaction was made by von Planta, Dr. Thomas . The transaction toke place on 30th April 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 41.450,00 CHF, based on an average price of 41,45 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 26th March 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 26th March 2024,
The Insider Transaction was made by von Planta, Dr. Thomas . The transaction toke place on 25th March 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 55.167,50 CHF, based on an average price of 45,97 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 26th March 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 26th March 2024,
The Insider Transaction was made by von Planta, Dr. Thomas . The transaction toke place on 22nd March 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 105.927,16 CHF, based on an average price of 48,15 CHF. The nature of the Investment was Buy.
BB Biotech AG: A reportable insider transaction was published on 21st February 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 21st February 2024,
The Insider Transaction was made by Thomsen, Prof. Dr. Mads Krogsgaard . The transaction toke place on 16th February 2024. The order was executed at the trading place SIX Swiss Exchange. . The aggregated volume was 874.766,15 CHF, based on an average price of 49,28 CHF. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 70 | 19th March 2025 | EQS Group AG | EQS |
| Corporate Research | 0 | - | - | Corporate Research |
| Short Seller (DE) | 1 | 15th December 2016 | Elliott Capital Advisors, L.P. | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.